Flooid Announces Strategic Partnership with FreedomPay to Expand Global Reach

The partnership will bring enhanced commerce functionality to Retailers around the world.

London, England, Jan. 13, 2023 (GLOBE NEWSWIRE) — Flooid today announces a strategic partnership with FreedomPay, the global leader in Next Level Commerce™, to bring industry-leading Retail solutions to merchants globally.

Powered by FreedomPay, Flooid allows merchants to connect their retail channels, removing barriers between online and in-store payments. FreedomPay’s data-driven commerce platform grants merchants access to valuable analytics and Business Intelligence platform to drive further customer engagement and loyalty through targeted offers and incentives, all within a frictionless integrated payment solution.

“Through this partnership with FreedomPay, we are bringing enhanced innovation, choice, and flexibility to retailers on the Flooid platform,” said Donna Stevens, Senior VP of Product and Marketing at Flooid. Our goal is to empower merchants with the tools they need to provide the best shopping experience to consumers globally.”

The FreedomPay platform enables enterprises to provide a consistent payment experience for their customers globally, creating a seamless and flexible retail experience managing security, data and loyalty all from a single, unified tech stack.

“The partnership between FreedomPay and Flooid will bring a world-class commerce experience to retailers and shoppers around the globe,” said Liesl Smith, Senior VP of Marketing and Sales Enablement at FreedomPay. “Together we are committed to delivering a seamless payment experience to customers, enabling an innovative and seamless omnichannel payment environment.”

About FreedomPay

FreedomPay’s Next Level Commerce™ platform transforms existing payment systems and processes from legacy to leading edge. As the premier choice for many of the largest companies across the globe in retail, hospitality, lodging, gaming, sports and entertainment, foodservice, education, healthcare and financial services, FreedomPay’s technology has been purposely built to deliver rock solid performance in the highly complex environment of global commerce. The company maintains a world-class security environment and was first to earn the coveted validation by the PCI Security Standards Council against Point-to-Point Encryption (P2PE/EMV) standard in North America. FreedomPay’s robust solutions across payments, security, identity, and data analytics are available in-store, online and on-mobile and are supported by rapid API adoption. The award winning FreedomPay Commerce Platform operates on a single, unified technology stack across multiple continents allowing enterprises to deliver an innovative Next Level experience on a global scale. www.freedompay.com

About Flooid

Flooid helps retailers create the seamless shopping experiences customers demand. Flooid’s unified commerce platform empowers merchants to sell to customers flexibly and consistently wherever they are and however they choose to shop. Our best of breed open ecosystem givers retailers the power to connect leading retail tech partners with a single unified commerce platform to engage with your shoppers, sell more effectively across channels and adapt to retail shopping changes we have yet to imagine.

Jennifer Tayebi
Hill+Knowlton Strategies for FreedomPay
+1 734 395 0780

GlobeNewswire Distribution ID 8729158

Azerion to simplify its reporting structure

Amsterdam, 13 January 2023 – Today, Azerion has announced that it will simplify its reporting structure by merging the parent company Azerion Group N.V. and Azerion Holding B.V.. As a result, the surviving entity Azerion Group N.V. will publish one report with the interim unaudited results for the fourth quarter 2022 and one set of consolidated financial statements for the full year 2022.

Ben Davey, CFO of Azerion, commented: “As we build our track record as a listed company, we continue to focus on simplifying our operating structure and improving transparency. Merging our two main reporting entities is an important step in this process.

The intention to affect this merger was announced on 28 October 2022 and the merger was completed on 31 December 2022.

Investor Relations



The companies in which Azerion Group N.V. directly and indirectly owns investments are separate legal entities. In this announcement “Azerion”, “Azerion Group” and “Group” are sometimes used for convenience where references are made to Azerion Group N.V. and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to Azerion Group N.V. and its subsidiaries in general or to those who work for them.

This press release is for information purposes only. The information contained in this press release does not purport to be full or complete and, in particular, is not intended to form the basis of any investment decision. No reliance may be placed by any person for any purpose on the information contained in this press release or its accuracy, fairness or completeness. Azerion will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided.

This press release may include forward-looking statements. All statements other than statements of historical facts may be forward-looking statements. Words and expressions such as believes, estimates, plans, projects, anticipates, expects, intends, may, will, should or other similar words or expressions are typically used to identify forward-looking statements. Forward-looking statements are subject to risks, uncertainties and other factors that are difficult to predict and that may cause the actual results of Azerion to differ materially from future results expressed or implied by such forward-looking statements. Any forward-looking statements reflect Azerion’s current views and assumptions based on information currently available to Azerion’s management. Forward-looking statements speak only as of the date they are made, and Azerion does not assume any obligation to update such statements, except as required by law. No assurances can be given that the forward-looking statements will be realised. No representation or warranty is made that any of these forward-looking statements will come to pass or that any estimated result will be achieved. Accordingly, no undue reliance should be placed on any forward-looking statements.

GlobeNewswire Distribution ID 1000777073

NAT Global Campus Signs 3 More High Flyers to Meet the Demand for Quality Education Online

Spiralling Growth in Consumer Demand for Natural Alternative Therapies Driving Healthcare Professionals to Spend More Time Learning Online

Niel Asher Education

Niel Asher Education

ORLANDO, Fla., Jan. 12, 2023 (GLOBE NEWSWIRE) — Niel Asher Education is pleased to announce that three dynamic new faculty members will join NAT Global Campus in spring 2023. The addition of these leading experts and innovators in the fields of Manual Medicine and Traditional Chinese Medicine further demonstrates its commitment to providing its student community with the highest standards of education online.

Dr. Constance Bradley, L.Ac., Ph.D., will present NAT courses on acupuncture and TCM. Dr. Bradley attended the US Air Force Academy, receiving a Bachelor of Science in Humanities in 2001. In 2002, she graduated from the University of Colorado, receiving a Master of Arts in Philosophy with an emphasis in Medical Ethics. In 2009 she received her Doctorate from the University of Utah.

“Niel Asher leads the way in providing top-notch continuing education, and I am honored to join their team. I look forward to sharing my Traditional Chinese Medicine expertise, and I am very excited to work with Niel Asher to create high-quality, informative courses,” she said.

Dr. Linda Bluestein, MD, is a Board-certified anesthesiologist, integrative pain medicine physician and former ballet dancer, who specializes in treating dancers and other athletes at increased risk of hyper-mobility and connective tissue disorders such as EDS.

Dr. Bluestein completed her anesthesiology residency at the Mayo Graduate School of Medicine after receiving her Medical Degree from the University of California, Los Angeles School of Medicine and is a member of the International Association for Dance Medicine and Science, the Performing Arts Medicine Association, and the Resources Committee for the Dance Healthy Alliance of Canada.

“I am thrilled to work with Niel Asher Education to create courses on symptomatic joint hypermobility.  It is exciting to work with them on educational offerings about these frequently misunderstood and complex conditions,” she said.

Dr. Elizabeth Wagner, Ph.D., earned her Doctorate in Physical Therapy from the University of Washington. She has also earned a certificate of competency in vestibular rehabilitation and is certified in Mechanical Diagnosis and Therapy.

“I am thrilled to collaborate with NAT to create high-quality continuing education courses. I look forward to contributing my 15 years of experience as a physical therapist and teacher to NAT’s ongoing efforts of supporting this vibrant community,” she said.

The NAT Global Campus has grown to become one of the largest online schools for Natural Alternative Therapies in manual medicine and serves over 100,000 students in over 40 countries.

NAT Global Campus’ Director Dani P. Marks stated, “Our most significant health challenges continually demand fresh takes and multidisciplinary approaches. This group of outstanding new faculty is joining a team of specialist teachers committed to deliver on this promise, and to help provide our students with the skills and knowledge to improve outcomes and provide outstanding care in their communities.”

Contact Information:
Dani Marks
Interim Director, NAT Global Campus

Related Images

Image 1: Niel Asher Education

This content was issued through the press release distribution service at Newswire.com.


GlobeNewswire Distribution ID 8729025

Amlan International to Showcase Natural Mineral Technology at International Production and Processing Expo (IPPE)

CHICAGO, Jan. 12, 2023 (GLOBE NEWSWIRE) — Amlan® International, the animal health business of Oil-Dri® Corporation of America, is pleased to announce its participation in the International Production and Processing Expo (IPPE) January 24-26, 2023, in Atlanta, GA. Attendees will learn more about the latest in feed technology for animal protein producers that optimize gut health through three exciting TECHTalks, a new product showcase featuring Phylox®, and two poster presentations during the International Poultry Scientific Forum (IPSF). Amlan is also proud to be the exclusive sponsor of the IPPE Media Center. Amlan looks forward to welcoming a global audience of animal production professionals and sharing more about its range of products with attendees, media and other exhibitors at its booth, B5453.

Last year at IPPE, Amlan expanded its product portfolio with the launch of Phylox (available in select international markets). Phylox is a research-backed, natural alternative to anticoccidial drugs that supports gut health naturally thus improving productivity and, in turn, driving producers’ profits. This year, Phylox will be highlighted during the expo’s new product showcase. Attendees can watch a video presentation to learn more about the company’s latest innovation.

“We look forward to speaking with producers about how Phylox, a bioactive blend of antiprotozoal phytochemicals with multiple modes of action, decreases the negative production and health effects of coccidiosis,” said Dr. Wade Robey, Vice President of Agriculture, Oil-Dri, and President, Amlan International. “Phylox is natural and can be used in “no antibiotics ever” (NAE) programs, has no withdrawal requirements, and can be fed in combination with anticoccidial vaccines preventing disease breakthrough.”

“We are excited about the success of our North American portfolio, which includes Sorbiam™ and Enterotec™. The industry reaction to these products created to optimize animal gut health has been tremendous,” according to Heath Wessels, Vice President of Sales, The Americas. “Working with our key customers, our products continue to demonstrate the efficacy of our mineral-based feed additives.”

Attendees can learn more about the latest in protein and feed technology presented during TECHTalks.

On Tuesday, January 24:

  • Dr. Marc Herpfer, VP, New Technologies, Oil-Dri Corporation of America, will present “Natural Mineral Technology as an Alternative to AGPs” in B Hall, Booth B8675 at 11:00 a.m.
  • Dr. Josh Payne, Dir. Technical Service, Poultry Guard, will present “Best Management Practices and Utilization of Clay-Based Litter Amendment for pH and Ammonia Control” in B Hall, Booth B3646 at 11:30 a.m.

On Wednesday, January 25:

  • Mike Donohue, VP, Agri Stats, Inc. will present “The Importance of 1%, The Effect of Efficiency on Sustainability and Economic Value” in B Hall, Booth B3646 at 10:00 a.m.

TECHTalks are an excellent way for us to provide valuable information on specific technical challenges the industry is facing,” says Dr. Aldo Rossi, Vice President, Innovation and Technical Service. “We are proud of our high-quality and efficacious mineral-based feed additives for poultry and livestock, and how they can improve the quality of animal protein. We look forward to sharing our solutions with producers.”

During the International Poultry Scientific Forum (IPSF) on January 23, Amlan experts will present two posters, selected by IPSF, detailing research designed to support optimal poultry intestinal health and bring the latest production technology to producers. The presentations will be from 4:00 p.m. to 6:00 p.m.:

  • Feeding Varium® produces growth performance similar to feeding an antibiotic on-farm, by Dr. Sara (LeAnn) Johnston, Technical Service Manager, Amlan International
  • A natural coccidiostat, Phylox Feed, improves performance, intestinal lesion scores, and fecal oocyst shedding of Eimeria-infected broilers, Dr. San (Chris) Ching, Senior Research Manager, Amlan International.

Amlan is continuing to proudly celebrate its 15th anniversary of providing natural mineral-based feed additives to the industry. The Amlan brand was introduced into the feed-additive market in 2007. Vertical integration allows Amlan to leverage Oil-Dri’s mineral science expertise to develop novel, natural feed additives. Oil-Dri launched its first mineral-based product, an industrial floor absorbent, in 1941, and since then has mined and processed a range of unique minerals for many applications. Oil-Dri has been active in the animal health market since the 1980s, with products that assist feed flowability and pellet binding.

“As the proud exclusive sponsor of the IPPE Media Center, Amlan looks forward to building relationships with media from around the world,” says Reagan Culbertson, Vice President of Strategic Marketing, B2B. “We hope media professionals will visit the Media Center to work, network and visit with our experts about Amlan’s unique and exciting mineral technology.”

For more information on Amlan International, please visit: www.amlan.com

Company Information

Amlan is the animal health business of Oil-Dri Corporation of America, a leading global manufacturer and marketer of sorbent minerals. Oil-Dri leverages over 80 years of expertise in mineral science to selectively mine and process its unique mineral for consumer and business-to-business markets. Oil-Dri Corporation of America doing business as “Amlan International” is a publicly traded stock on the New York Stock Exchange (NYSE: ODC). Amlan International sells feed additives across the world. Product availability may vary by country, associated claims do not constitute medical claims and may differ based on government requirements.

Reagan Culbertson
Media Contact

GlobeNewswire Distribution ID 8729202

UPDATE – IIBA and HRPA Announce Strategic Partnership

New Certificate Program Incorporates Business Analysis to Enhance HR Function, Improving Business Outcomes

TORONTO, Jan. 12, 2023 (GLOBE NEWSWIRE) — The International Institute of Business Analysis™ (IIBA®) and the Human Resources Professionals Association (HRPA) are proud to announce their strategic partnership. HRPA, serving the Ontario Province, have been advocating for the human resources profession for over 40 years to ensure that HR professionals have the most up-to-date tools and advanced skills needed to lead workplaces into the future. IIBA, with 30,000 members around the world, is leading the global business analysis community and is shaping professional standards to achieve better outcomes through better analysis.

Business analysis skills are strategically important to today’s CHRO tasked with taking on complex organizational challenges, as expectations of the HR function are increasing for advanced strategic thinking in defining solutions that deliver organizational value. HR needs a playbook of repeatable processes of uncovering the real business issues to solve, better techniques for determining solutions that are impactful, and a focused way of assembling compelling business cases that gain organizational support. To help HR professionals gain these skills, HRPA partnered with IIBA.

The partnership between IIBA and HRPA is a pivotal relationship that emphasizes the value of leveraging analysis and data to drive business decisions and optimize HR practices. Through the combination of cutting-edge research, industry insights, and best practices, this partnership helps to ensure that HR professionals have the necessary business analysis skills and knowledge to effectively lead their organizations into the future.

“Coming into the post-pandemic era there is a need for workplaces to increase learning agility, simplify cumbersome people processes, radically transform the employee experience, and turn their attention to increased organizational effectiveness to evolve within the new world of work,” said Kris Tierney, Vice President HR and Learning, HRPA. “We wanted to offer our members a program built on the proven standards of IIBA and highlight for HR professionals the value of business analysis in remarkably improving enterprise outcomes.”

To help the HR profession meet the challenges of this new world and lead at a higher level, HRPA in association with the IIBA have built the Radical HR: Upskilling from Service Provider to Solution Expert program using the foundation of IIBA’s Entry Certificate in Business Analysis™ (IIBA-ECBA). This innovative course is a five-module certificate program designed to enable organizational change by empowering participants to identify opportunities, define needs, and recommend solutions to deliver stakeholder value in the Human Resources field. By the end of the program, participants will receive the Human Resources Solutions Certificate (HRSC) and be equipped to sit IIBA’s ECBA™ exam.

“This program is focused on giving HR practitioners’ practical business analysis tools to assist in navigating complex projects and change. These skills will set up HR diagnostics to be clear and strategic for your clients and leaders,” said Mary Madigan Lee, Chief People Officer, City of Toronto.

“HRPA and IIBA realized business analysis skills needed to be stronger in HR professionals to support the pace of change faced by their members. The partnership with HRPA brings the value of business analysis to achieve better business outcomes to HR professionals in a way that is practical and resonates for their unique needs,” said Keith Ellis, Chief Engagement and Growth Officer, IIBA. “What makes this program so unique is that it provides a clear path for HR professionals to transform from being a service provider to being the solution designer, influencer, and change partner that top leadership requires.”

73% of pilot participants felt they gained a sense of confidence to impact and influence change after completing the course.1 All participants believe that business analysis techniques and skills are essential to a high-functioning HR department. The tools learned within this program will help participants better use business analysis foundations to conduct comprehensive needs analyses, create evidence-based solutions, and support organizational transformation, employee development and performance management, succession planning, and other key practices. Participants will advance their careers by gaining the necessary skills to deliver value-creating solutions that meet stakeholder needs across the business. Individuals exiting the program report have a feeling of greater individual and team effectiveness in evolving core HR processes, as well as greater confidence, to tackle complex change initiatives.

Follow the link below to register for the course:
Radical HR: Upskilling from Service Provider to Solution Expert

Business analysis provides tremendous value to a wide range of industries and roles by helping organizations sense and enable change by defining needs and recommending solutions that deliver value. Join IIBA as a strategic partner and become part of a global network of experts who work towards delivering better outcomes through business analysis.

To learn more about IIBA’s Strategic Partnerships please visit https://www.iiba.org/organizational-programs/strategic-partnerships/.

About IIBA
International Institute of Business Analysis™ (IIBA®) is a professional association leading the global business analysis community to achieve better outcomes through better analysis. With over 30,000 Members and certified professionals, and more than 120 Chapters, 1,200 volunteers, and 600 partners worldwide, IIBA supports the recognition of the profession within organizations, enables networking and community engagement, provides foundational standards and resources, and offers internationally recognized certification programs for career advancement. For more information, visit iiba.org.

About HRPA
At the Human Resources Professionals Association, we believe that better HR makes business better. The HRPA ensures that our 24,000 members and students have the most up-to-date tools and the advanced skills to lead our workplaces into the future. We regulate HR professionals in the public interest. Our members are held to the province’s highest standards, so Ontario workplaces can trust us to help unlock business growth and optimize employee potential. Learn more at hrpa.ca.

  1. Source: IIBA post course-assessment of pilot participants

Media Contacts
Shyra Wells, Communications & Media Specialist
+1 (289) 212-3657

Public Relations & Communications Department

GlobeNewswire Distribution ID 8729162

Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines

Sabin Vaccine Institute Awarded BARDA Contract With Funding Potential up to $214M for Ebola Sudan and Marburg Vaccines

The Sabin Vaccine Institute will produce up to 100,000 doses of Sabin’s Ebola Sudan vaccine as part of a new, multi-year contract with BARDA

WASHINGTON, Jan. 12, 2023 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded Sabin a multi-year contract with funding potential for up to $214 million to advance the development and production of single-dose vaccine candidates for Ebola Sudan and Marburg virus diseases.

There are currently no licensed vaccines against Ebola Sudan and Marburg viruses, which cause hemorrhagic fever and kill approximately half the people infected.

BARDA, part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response (ASPR), will initially invest approximately $35 million to produce up to 100,000 doses of Sabin’s Ebola Sudan virus (ChAd3-SUDV) vaccine. These vaccines may be used as part of ongoing U.S. preparedness efforts and in response to future global outbreaks.

The Sabin vaccine was the first to arrive in Uganda during the recent Ebola Sudan virus outbreak that caused 55 deaths after the World Health Organization included it as one of three vaccines for possible use in an outbreak trial in Uganda. The country declared the Ebola Sudan outbreak had ended on January 11, four months after the first confirmed case.

“Sabin successfully delivered Ebola Sudan vaccine doses to Uganda within 79 days of the start of the outbreak – quite an impressive accomplishment,” says Sabin Chief Executive Officer Amy Finan. “This new contract enables Sabin to produce up to 100,000 doses so the world is prepared in advance for future outbreaks.”

In addition to participating in recent outbreak activities, Sabin continues its Sudan development plan and has initiated Phase 2 clinical trial planning in Uganda and Kenya. Based on previous clinical trials, Sabin’s Ebola Sudan vaccine is safe and immunogenic, and in nonhuman primate studies has demonstrated rapid protection, durability up to 12 months, and efficacy.

In addition to Sabin’s ChAd3-SUDV vaccine, the contract also includes support to manufacture Sabin’s vaccine against Marburg virus (ChAd3-MARV), which would generate doses that could also be used in trials and in response to a possible Marburg virus outbreak. As recently as last July, two people in Ghana died after being infected with Marburg virus, reinforcing the urgent need for a vaccine.

The new contract leverages a partnership with BARDA that began in 2019, when the agency awarded Sabin another multi-year contract valued at $128 million to further the development of vaccines against both the Marburg and Ebola Sudan viruses.

“BARDA has been a supportive partner as we take these essential steps in pandemic preparedness,” said Finan. “The Ebola Sudan outbreak in Uganda underscored the critical need for readily available solutions. We’ll now have ample material to respond quickly to such an outbreak in the future.”

This project will be funded in whole with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50123C00010.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine.

About Ebola Sudan and Marburg

Ebola Sudan and Marburg are members of the filovirus family. Both can cause severe hemorrhagic fever in humans and nonhuman primates. No therapeutic treatment of these hemorrhagic fevers has been licensed to date. Marburg and Ebola viruses are transmitted to humans by infected animals, particularly fruit bats. Once a human is infected, the virus can spread to others through close personal contact or contact with bodily fluids. Isolation of infected people is currently the centerpiece of filovirus control.

Marburg was the first filovirus to be recognized in 1967 when outbreaks of hemorrhagic fever were reported in a few Europe-based laboratories including in the town of Marburg, Germany. Ebola was identified in 1976 when two simultaneous outbreaks occurred in northern Zaire (now the DRC) in a village near the Ebola River and in southern Sudan. The outbreaks involved what eventually proved to be two different species of Ebola virus; both were named after the nations in which they were discovered.

For media inquiries:


Media Contact:
Monika Guttman
Media Relations Specialist
Sabin Vaccine Institute
+1 (202) 662-1841

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/539c9127-e5d6-4b32-9e89-780f7461314b

GlobeNewswire Distribution ID 8728283